Drugs / Cindilimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05803928 | Jan → Nov 2024 overdue | hepatocellular carcinoma | Hua Li | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cindilimab | “Cindilimab is a human immunoglobulin G4 (IgG4) monoclonal antibody that specifically binds to PD-1 molecules on the surface of T cells, thereby blocking the programmed death...” NCT05803928 ↗ |
| Action | Inhibit | “thereby blocking the programmed death receptor-1 (PD-1)/programmed death receptor-1 ligand (PD-L1) pathway” NCT05803928 ↗ |
| Modality | Monoclonal antibody | “Cindilimab is a human immunoglobulin G4 (IgG4) monoclonal antibody” NCT05803928 ↗ |